The use of recombinant factor VIIa in a Jehovah’s Witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Waddington DP, McAuley FT, Hanley JP, Summerfield GP
Br J Haematol 2002;119(1):286-288.
NATA Rating :
Review by : Aldouri M
Management of bleeding in patients who refuse blood transfusion may prove to be a therapeutic challenge, and therefore blood sparing modes of therapy need to be considered. In severe surgical or traumatic bleeding, administration of rFVIIa may result in an effective response and should be considered early in the course of management.
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.